Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.

This week, we break down:

• Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitis

• The future of autoimmune disease treatment: genetically modified T cells

• What policies people actually support (and will pay for) to reduce skin cancer rates

• JAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch for

• The latest on rising contact allergens: which ones are on the move and why

Packed with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.

Don’t miss out—hit play for your weekly dose of dermatology insights!

For links to all articles visit ScholarsinMedicine.com

1.  Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
2.  Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid
3.  Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry
4.  Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
5.  Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
6.  Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries
7. North American Contact Dermatitis Group Patch Test Results: 2021–2022

Ever feel overwhelmed by the flood of alopecia treatments and supplements?

Join the Derms on Drugs as we cut through the noise with Dr. Michelle Tarbox, diving deep into the practical side of managing alopecia for dermatology providers.

In this episode, we tackle:

• Which labs to order for telogen effluvium
• Which hair loss supplements are actually worth recommending
• The truth about red light helmets
• How and when to use prescription therapies for hair loss
• Can shampoo really help with alopecia?

Tune in for expert insights, practical tips, and a healthy dose of humor—perfect for medical providers who want to stay ahead in dermatology without getting lost in the latest hype.

Listen now for all the answers—and maybe a few laughs!

Hair loss is common and devastating, both to the person losing their hair and the dermatology provider taking care of them.  Derms on Drugs to the rescue.  In part one of our deep dive into hair loss we cover three big topics:  1) What supplements for hair loss actually work?  You'll have heard (ad nauseum) about some of them, but we'll also bring you some ideas for cheap supplements you haven't heard of that actually work; 2) Do we really need to do lab work-ups in patients with telogen effluvium? and 3) What's the state of the art when it comes to diagnosing and managing folliculitis decalvans?  Join us for another episode with our trademark mix of evidence and banter!  #DermatologyPodcast #HairLoss #DermsOnDrugs #Alopecia

Produced by ScholarsinMedicine.com

ScholarsinMedicine.com⁠

1.  Management of folliculitis decalvans: The EADV task force on hair diseases position statement
2.  Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience
3.  Impact of Laboratory Work Up and Supplementation on Alopecia Patients: A Single-Center Retrospective Chart Review
4.  Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss A Systematic Review

Join Derms on Drugs for a must-hear episode packed with practical dermatology updates!

Discover if Nutrafol Acne delivers, which skin care ingredients top cosmetic dermatologists swear by, and the latest breakthroughs for hand eczema. Plus, is Zoryve Foam a game-changer for psoriasis? And what’s the deal with PRAME staining for benign nevi? Get actionable insights to elevate your practice along with our usual banter. 

Derms on Drugs is produced by Scholars in Medicine.

Resource links can be found at: Scholarsinmedicine.com
1.  A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial for the Efficacy and Safety of a Novel Nutraceutical for Mild-to-Moderate Acne
2.  Skincare Ingredients Recommended by Cosmetic Dermatologists: A Delphi Consensus Study
3.  Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial
4.  Oral roflumilast for the treatment of chronic hand eczema: a retrospective case series
5.  Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body
6.  Clinicopathologic Features of PRAME-Positive Common Melanocytic Nevi: A Case-Control Study

 Skyrocketing drug prices are hitting dermatology hard. Why are Americans paying more than other countries? Are Pharmacy Benefit Managers (PBMs) or pharmaceutical companies to blame? Join Derms on Drugs as our experts pull back the curtain on the broken system driving costs. Get insider insights, practical takeaways, and our trademark banter to navigate this mess as a clinician.

Derms on Drugs is a production of Scholarsinmedicine.com

1.  Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US
2.  Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis
3.  AI Description and Answers About How Drug Pricing Works

Scholarsinmedicine.com

Join Derms on Drugs for a riveting dive into artificial intelligence and automated skin cancer detection.

World-renowned expert Dr. Laura Ferris, with 20 years in the field, breaks down cutting-edge research and predicts the future of dermatology. Will AI "terminate" dermatologists or empower us to focus on complex cases and patient care? Expect fresh insights, practical takeaways, and lively banter that’ll make you a smarter clinician. Don’t miss this chance to stay ahead in the AI revolution!

Derms on Drugs is produced by ⁠Scholars In Medicine

For Resources links visit: ⁠Scholars In Medicine⁠
1.  Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening?
2.  3D Total-Body Photography in Patients at High Risk for Melanoma
3.  Promises and Pitfalls of 3D Total-Body Photography for Melanoma Early Detection
4.  Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance
5.  Standard Dermatoscope Images vs an Autonomous Total Body Photography and Dermoscopic Imaging Device

Tune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo?

Plus, discover new skin-gut-immune connections, tackle cancer immunotherapy-induced pemphigoid, and learn how to manage premenstrual rash flares in atopic dermatitis, contact dermatitis, and autoimmune progesterone dermatitis. Join our fun, banter-filled discussion to stay ahead in dermatology!

In This Episode:
Stage 3A Melanoma: Is adjuvant therapy worth it, and what’s the best option?
Dermatomyositis: Consequences of misdiagnosis and delayed diagnosis
Vitiligo: Could hydroxychloroquine be a game-changer over NBUVB?
Skin Inflammation: A key driver of food allergy
Pemphigoid: Insights into immunotherapy-induced cases
Premenstrual Rashes: Managing flares in atopic

1.  Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
2.  Patterns and Clinical Implications of Misdiagnosis in Dermatomyositis
3.  Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial
4.  Skin damage signals mediate allergic sensitization to spatially unlinked antigen
5.  Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous Pemphigoid
6.  The impact of the menstrual cycle on exacerbations of atopic dermatitis: a systematic review
7.  Nickel contact allergy and menstrual cycle
8.  Autoimmune progesterone dermatitis: Update and insights

Derms on Drugs is produced by ⁠⁠Scholars in Medicine.com

Should dermatologists offer Image Guided Superficial Radiation Therapy (IGSRT) in-office or refer radiation oncologists when radiation is appropriate? Join Derms on Drugs as we tackle this "burning" question with two expert radiation oncologists. While dermatologists are THE skin cancer experts, radiation therapy isn't our usual domain— so is IGSRT a game-changer for your practice or too far outside our realm? Explore clinical insights, practical considerations, and the latest evidence to guide your decision-making. Perfect for dermatologists, PAs, NPs, residents, medical students, and pharma professionals in dermatology seeking to stay ahead of the curve. Tune in to discover if IGSRT could light up your approach to patient care—or leave you glowing in the dark.


#Dermatology #SkinCancer #IGSRT #RadiationTherapy #DermEducation
1.  Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasoundguided superficial radiotherapy, a multiinstitutional study

ScholarsInMedicine.com

2.  The Role of Image-Guided Superficial Radiation Therapy in the Treatment of Nonmelanoma Skin Cancer
3.  Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study

Buckle up for a whirlwind tour of the hottest dermatology literature. This week, we’ve got the deets on:

• Cutaneous squamous cell carcinoma: What predicts when it'll go rogue and metastasize? Spoiler: It’s not just bad vibes.
• Oral lichen planus: Turns out, its cancer risk is sneakier than a derm resident dodging clinic.
• Remibrutinib for CSU: The first oral game-changer for chronic spontaneous urticaria. Hives, meet your match!
• Psoriasis biologics: Which systemic treatments keep infections at bay? We’ve got the lowdown.
• Chemo’s conundrum: One bizarre trick to stop a cutaneous side effects

Hidradenitis suppurativa itch: Dermeleve’s here to make HS patients stop scratching and start living.
Join us for laughs, learning, and maybe a few gasps as we unpack the science that’s got the derm world buzzing. Perfect for dermatologists, PAs, NPs, pharma folks, and students who live for skin-deep insights. Subscribe, share, and let’s make dermatology lit!  #DermatologyPodcast #DermLife

ScholarsinMedicine.com⁠

When a pathology report says 'melanoma,' the stakes are high. How confident are you in the diagnosis? Should you order gene expression profiling for better prognostic insights—or is it overrated?

Join the Derms on Drugs as we dig into the challenges of melanoma diagnosis and management. This week, we’re thrilled to feature Dr. Whitney High from the University of Colorado, the best-of-the-best dermatopathology expert, to share evidence-based answers with the Derms on Drugs flare our listeners expect.  

Derms on Drugs is brought to you by ⁠⁠Scholars in Medicine.⁠

Resource links for this episode are available at ⁠Scholars in Medicine⁠.
1.  Society of Surgical Oncology Consensus Statement: Assessing the Evidence for and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma

2.  31-GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort

3.  CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients With Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines

4.  CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality